These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: II. Functional profile in comparison to clozapine and haloperidol. Millan MJ; Schreiber R; Dekeyne A; Rivet JM; Bervoets K; Mavridis M; Sebban C; Maurel-Remy S; Newman-Tancredi A; Spedding M; Muller O; Lavielle G; Brocco M J Pharmacol Exp Ther; 1998 Sep; 286(3):1356-73. PubMed ID: 9732399 [TBL] [Abstract][Full Text] [Related]
24. Antagonist properties of the novel antipsychotic, S16924, at cloned, human serotonin 5-HT2C receptors: a parallel phosphatidylinositol and calcium accumulation comparison with clozapine and haloperidol. Cussac D; Newman-Tancredi A; Nicolas JP; Boutin JA; Millan MJ Naunyn Schmiedebergs Arch Pharmacol; 2000 May; 361(5):549-54. PubMed ID: 10832610 [TBL] [Abstract][Full Text] [Related]
25. The effects of clozapine and haloperidol on serotonin-1A, -2A and -2C receptor gene expression and serotonin metabolism in the rat forebrain. Burnet PW; Chen CP; McGowan S; Franklin M; Harrison PJ Neuroscience; 1996 Jul; 73(2):531-40. PubMed ID: 8783268 [TBL] [Abstract][Full Text] [Related]
26. High-affinity agonist binding correlates with efficacy (intrinsic activity) at the human serotonin 5-HT2A and 5-HT2C receptors: evidence favoring the ternary complex and two-state models of agonist action. Fitzgerald LW; Conklin DS; Krause CM; Marshall AP; Patterson JP; Tran DP; Iyer G; Kostich WA; Largent BL; Hartig PR J Neurochem; 1999 May; 72(5):2127-34. PubMed ID: 10217294 [TBL] [Abstract][Full Text] [Related]
27. (1-(2,5-dimethoxy-4 iodophenyl)-2-aminopropane)-induced head-twitches in the rat are mediated by 5-hydroxytryptamine (5-HT) 2A receptors: modulation by novel 5-HT2A/2C antagonists, D1 antagonists and 5-HT1A agonists. Schreiber R; Brocco M; Audinot V; Gobert A; Veiga S; Millan MJ J Pharmacol Exp Ther; 1995 Apr; 273(1):101-12. PubMed ID: 7714755 [TBL] [Abstract][Full Text] [Related]
28. In vitro autoradiography of serotonin 5-HT(2A/2C) receptor-activated G protein: guanosine-5'-(gamma-[(35)S]thio)triphosphate binding in rat brain. Adlersberg M; Arango V; Hsiung S; Mann JJ; Underwood MD; Liu K; Kassir SA; Ruggiero DA; Tamir H J Neurosci Res; 2000 Sep; 61(6):674-85. PubMed ID: 10972964 [TBL] [Abstract][Full Text] [Related]
29. Lack of cross-tolerance for hypophagia induced by DOI versus m-CPP suggests separate mediation by 5-HT2A and 5-HT2C receptors, respectively. Aulakh CS; Mazzola-Pomietto P; Hulihan-Giblin BA; Murphy DL Neuropsychopharmacology; 1995 Aug; 13(1):1-8. PubMed ID: 8526967 [TBL] [Abstract][Full Text] [Related]
30. Limited participation of 5-HT(1A) and 5-HT(2A/2C) receptors in the clozapine-induced Fos-protein expression in rat forebrain regions. Sebens JB; Kuipers SD; Koch T; Ter Horst GJ; Korf J Eur J Pharmacol; 2000 Nov; 408(1):11-7. PubMed ID: 11070178 [TBL] [Abstract][Full Text] [Related]
31. Pharmacological characteristics and regulation of 5-HT receptor-stimulated phosphoinositide hydrolysis in the rat spinal cord. Toscano E; Romero G; Oset C; Del Río J Gen Pharmacol; 1999 Mar; 32(3):351-8. PubMed ID: 10211591 [TBL] [Abstract][Full Text] [Related]
32. Modification of haloperidol-induced pattern of c-fos expression by serotonin agonists. Tremblay PO; Gervais J; Rouillard C Eur J Neurosci; 1998 Nov; 10(11):3546-55. PubMed ID: 9824467 [TBL] [Abstract][Full Text] [Related]
33. Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor. Pälvimäki EP; Roth BL; Majasuo H; Laakso A; Kuoppamäki M; Syvälahti E; Hietala J Psychopharmacology (Berl); 1996 Aug; 126(3):234-40. PubMed ID: 8876023 [TBL] [Abstract][Full Text] [Related]
34. Time course of dopamine-D2 and serotonin-5-HT2 receptor occupancy rates by haloperidol and clozapine in vivo. Sumiyoshi T; Kido H; Sakamoto H; Urasaki K; Suzuki K; Yamaguchi N; Mori H; Shiba K; Yokogawa K; Ichimura F Jpn J Psychiatry Neurol; 1993 Mar; 47(1):131-7. PubMed ID: 8411785 [TBL] [Abstract][Full Text] [Related]
35. Paradoxical effects of lithium on serotonergic receptor function: an immunocytochemical, behavioural and autoradiographic study. Moorman JM; Leslie RA Neuropharmacology; 1998; 37(3):357-74. PubMed ID: 9681934 [TBL] [Abstract][Full Text] [Related]
36. Clozapine and haloperidol differentially alter the constitutive activity of central serotonin2C receptors in vivo. Navailles S; De Deurwaerdère P; Spampinato U Biol Psychiatry; 2006 Mar; 59(6):568-75. PubMed ID: 16182256 [TBL] [Abstract][Full Text] [Related]
37. Relative efficacies of piperazines at the phosphoinositide hydrolysis-linked serotonergic (5-HT-2 and 5-HT-1c) receptors. Conn PJ; Sanders-Bush E J Pharmacol Exp Ther; 1987 Aug; 242(2):552-7. PubMed ID: 3039120 [TBL] [Abstract][Full Text] [Related]
38. Distribution and characterization of [3H]mesulergine binding in human brain postmortem. Marazziti D; Rossi A; Giannaccini G; Zavaglia KM; Dell'Osso L; Lucacchini A; Cassano GB Eur Neuropsychopharmacol; 1999 Dec; 10(1):21-6. PubMed ID: 10647092 [TBL] [Abstract][Full Text] [Related]
39. The effect of streptozotocin-induced diabetes on dopamine2, serotonin1A and serotonin2A receptors in the rat brain. Sumiyoshi T; Ichikawa J; Meltzer HY Neuropsychopharmacology; 1997 Mar; 16(3):183-90. PubMed ID: 9138434 [TBL] [Abstract][Full Text] [Related]
40. Effects of serotonergic agents on the up-regulation of dopamine D2 receptors induced by haloperidol in rat striatum. Ishikane T; Kusumi I; Matsubara R; Matsubara S; Koyama T Eur J Pharmacol; 1997 Feb; 321(2):163-9. PubMed ID: 9063684 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]